LONDON – The discovery of a new way to prevent cells from producing tumor necrosis factor (TNF) could one day lead to the development of more specific treatments for conditions such as rheumatoid arthritis, Crohn's disease and sepsis.
Quality management problems at its contract manufacturer, Ben Venue Laboratories Inc., have forced Clavis Pharma ASA to slow recruitment in a Phase III trial of elacytarabine in late-stage acute myeloid leukemia (AML) and will result in a delay of one quarter in the reporting of its results.
LONDON – Nanomedicine specialist Midatech Ltd. closed a £6.3 million (US$9.7 million) funding round as it confirmed the formal launch of its joint venture with MonoSol Rx, in which the two partners will develop a gold nanoparticle-based formulation of insulin, designed to be delivered via a patch that adheres to the inside of the mouth.
LONDON – A protein that can steer the estrogen receptor protein to different parts of the genome in cancer cells probably helps to determine the outcome of breast cancer, a new study has found.
LONDON – ProFibrix NV announced positive U.S. Phase II data for its Fibrocaps tissue sealant to add to positive results from the European Phase II published in November 2011, and is talking to investors at the J.P. Morgan Healthcare conference in San Francisco this week, looking to raise €20 million to €25 million (US$25.4 million to $31.8 million) for a pivotal Phase III trial.
BioInvent International AB could earn up to €11 million (US$14 million) in up-front and milestone payments, as well as royalties on eventual product sales, from a cancer antibody discovery collaboration with Les Laboratoires Servier SA.
Apogenix AG took in €7.5 million (US$9.6 million) in new investments, plus a further €2.3 million in government funding, to continue clinical development of its lead molecule, APG101, and to fund associated biomarker research.
• Alchemia Ltd., of Brisbane, Australia, said it randomized the first patient in its pivotal Phase III study of HA-Irinotecan, its lead cancer drug that uses the firm's HyACT technology to target irinotecan directly to cancer cells.
LONDON – The identification of a gene that plays an important role in the development of the pancreas will give a boost to efforts to create insulin-producing pancreatic beta cells for the treatment of Type I diabetes.
RSS